Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, and Bladder and Urothelial Cancer Treatments.
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
Contrastive learning enhances fairness in pathology artificial intelligence systems
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
A pathology foundation model for cancer diagnosis and prognosis prediction
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
The Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper?
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors